HBIO HARVARD BIOSCIENCE INC NASDAQ · United States

HARVARD BIOSCIENCE INC (HBIO) news

HARVARD BIOSCIENCE INC is a public biotech or pharmaceutical company listed on NASDAQ under the ticker HBIO, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest HARVARD BIOSCIENCE INC news

We have not published a story on HARVARD BIOSCIENCE INC yet. When there is news, it will appear here.

HARVARD BIOSCIENCE INC annual financials

Line	FY2025	FY2024
Research and development	$8.8 million	$10.4 million
Net income (loss)	-$56.7 million	-$12.4 million
Cash from operations	$6.7 million	$1.4 million
Cash and equivalents	$8.6 million	$4.1 million

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $6.5 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about HARVARD BIOSCIENCE INC

What is the ticker symbol of HARVARD BIOSCIENCE INC?

HARVARD BIOSCIENCE INC trades under the ticker HBIO on NASDAQ.

Where is HARVARD BIOSCIENCE INC listed?

HARVARD BIOSCIENCE INC is listed on NASDAQ.

Which country or territory is HARVARD BIOSCIENCE INC listed under?

Our directory records HARVARD BIOSCIENCE INC under United States.

Does aibio.space cover HARVARD BIOSCIENCE INC?

aibio.space lists HARVARD BIOSCIENCE INC among 2,820 public biotech companies and publishes its news here as stories appear.

Is HARVARD BIOSCIENCE INC profitable?

HARVARD BIOSCIENCE INC reported a net loss of $56.7 million for the fiscal year ended Dec 31, 2025, and generated $6.7 million of cash from operations, per its annual report to the SEC.

How much does HARVARD BIOSCIENCE INC spend on research and development?

$8.8 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does HARVARD BIOSCIENCE INC have?

$6.5 million in cash at Jun 30, 2026, per its 10-Q.

Investor discussion: HARVARD BIOSCIENCE INC

Members talk about HARVARD BIOSCIENCE INC (HBIO). Reader posts, not aibio.space reporting, and not investment advice.

Rules

Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at HARVARD BIOSCIENCE INC, newest first. Each line links the filing it comes from.

Aug 11, 2026Listings
Reported a reverse stock split. SEC Form 8-K (Items 7.01,9.01). Source
Jun 2, 2026Listings
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). Source
May 12, 2026Listings
Reported a reverse stock split. SEC Form 8-K (Items 7.01,9.01). Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:HBIO on TradingView.

Listing details

Company: HARVARD BIOSCIENCE INC
Ticker: HBIO
Listing: NASDAQ
Country or territory: United States

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction